Providing Public Comments on Medicare’s Restrictive Coverage Policy for Amyloid PET

Presented by 

Program Overview:

The Centers for Medicare and Medicaid Services (CMS) recently began the process of reconsidering its 2013 decision to significantly limit Medicare coverage of amyloid beta (Aß) proton emission tomography (PET) scans. This is an important opportunity to greatly expand access to this critical diagnostic tool for millions of patients at risk of developing Alzheimer’s disease. Between 2012 and 2020, more than 30 academic manuscripts have been published showing how Aß PET scans have empirically and repeatedly – even in the absence of disease-modifying therapeutics – demonstrated significant clinical utility by causing changed clinical management, changed patient diagnoses, and improved provider confidence.  Furthermore, these diagnostic tools have the potential to help identify many more patients who could most benefit from new therapies, improving outcomes for millions.

Speakers:

• Laura Cohen, Eli Lilly and Company

Continuing Education (CE) Information
No continuing education (CE) credit will be offered for this webinar.

Please note: This webinar is intended for US audiences only. If you are located outside of the United States, please do not register.